It is still unknown how systemic inflammation, lymphoid organ function, and lymphoma activity relate to one another in patients treated with CD19-targeting CAR-T-cell immunotherapy and what that means for treatment response and side effects. The gene discussed is CD19; the disease is lymphoma.